Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

4±â º´±â ÇÏÀεξϿ¡¼­ ¼±Çà Ç×¾ÏÈ­Çпä¹ýÈÄ ¹æ»ç¼±Ä¡·á Induction Chemotherapy Followed by Radiotherapy for Stage IV Hypopharyngeal Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2004³â 22±Ç 4È£ p.247 ~ 253
¼Ò¼Ó »ó¼¼Á¤º¸
°­±â¹®/Kang KM ä±Ô¿µ/±èÁøÆò/ÀÌ¿ø¼·

Abstract

¸ñ Àû: ÇÏÀεξÏÀº ´ëºÎºÐ ÁøÇàµÇ¾î Áø´ÜÀÌ µÇ¸ç ¿¹ÈÄ°¡ ºÒ·®ÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ¿¡ 4±â º´±â ÇÏÀεξϿ¡¼­ ¼±Çà Ç×¾ÏÈ­Çпä¹ý ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏ¿© ¹ÝÀÀ°ú »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1989³â 7¿ùºÎÅÍ 2000³â 2¿ù±îÁö ¿ø°ÝÀüÀÌ°¡ ¾ø¾ú´ø AJCC º´±â 4±âÀÇ ÇÏÀεξÏÀ¸·Î Áø´ÜµÇ¾î ¼±Çà Ç×¾ÏÈ­Çпä¹ýÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹Þ¾Ò´ø 18¿¹¸¦ ´ë»óÀ¸·Î ÈÄÇâÀû ºÐ¼®À» ÇÏ¿´´Ù. ¼±ÇàÈ­Çпä¹ýÀº 5-FU¿Í cisplatinÀ» º´¿ëÇÏ¿© 3ÁÖ °£°ÝÀ¸·Î ¸ðµç ȯÀÚ¿¡¼­ 2ȸ ½ÃÇàÇÏ¿´´Ù. Ãѹæ»ç¼±·®Àº ¿ø¹ßº´¼Ò¿Í ÀüÀÌµÈ ÀÓÆÄÀý¿¡ 68.4¢¦72.0 Gy±îÁö Á¶»çÇÏ¿´´Ù(Áß¾Ó°ª: 70.2 Gy).

°á °ú: ÃßÀû°üÂû±â°£Àº 7°³¿ù¿¡¼­ 99°³¿ùÀ̾ú´Ù(Áß¾Ó°ª: 28°³¿ù). 3³â »ýÁ¸À² ¹× ¹«º´»ýÁ¸À²Àº °¢°¢ 41.7%, 31.1%¿´´Ù. 6¿¹(33.3%)¿¡¼­ 3³â ÀÌ»ó ÈĵΠº¸Á¸ÀÌ °¡´ÉÇÏ¿´´Ù. ¼±Çà Ç×¾ÏÈ­Çпä¹ý ÈÄ 16¿¹(88.8%)¿¡¼­ ºÎºÐ°üÇظ¦ º¸¿´°í, ¿ÏÀü°üÇØ, ¹«¹ÝÀÀÀº °¢°¢ 1¿¹(5.6%)¿¡¼­ °üÂûµÇ¾ú´Ù. ¸ðµç Ä¡·á°¡ ³¡³­ ÈÄ Ä¡·á ¹ÝÀÀÀ¸·Î ¿ÏÀü°üÇØ´Â 13¿¹(72.2%), ºÎºÐ°üÇØ°¡ 5¿¹(27.8%)·Î ¹ÝÀÀ·üÀº 100%¿´´Ù. »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿¹ÈÄÀÎÀÚ¿¡ ´ëÇÑ ºÐ¼®¿¡¼­ ¼±Çà Ç×¾ÏÈ­Çпä¹ý°ú ¹æ»ç¼±Ä¡·á ÈÄ¿¡ ¿ÏÀü°üÇظ¦ º¸ÀÎ ±º°ú ºÎºÐ°üÇظ¦ º¸ÀÎ ±ºÀÇ 3³â »ýÁ¸À²°ú ¹«º´»ýÁ¸À²ÀÌ °¢°¢ 43.1%, 20.0%¿Í 39.6%, 20.0%·Î ÀǹÌÀÖ´Â Â÷À̸¦ º¸¿´À¸¸ç(p=0.0003, p=0.002) ¸ðµç Ä¡·á°¡ ³¡³­ ÈÄ ÃÖÁ¾ Ä¡·á ¹ÝÀÀ¸¸ÀÌ Åë°èÇÐÀûÀ¸·Î À¯ÀǼºÀÌ ÀÖ¾ú´Ù.

°á ·Ð: 4±â º´±â ÇÏÀεξϿ¡¼­ ¼±Çà Ç×¾ÏÈ­Çпä¹ý ÈÄÀÇ ¹æ»ç¼±Ä¡·á´Â ½É°¢ÇÑ ºÎÀÛ¿ë¾øÀÌ È¿°úÀûÀ̾ú´Ù.

Purpose: Hypopharyngeal cancer is diagnosed at the advanced stage in most cases, which the prognosis known to be poor. Thus, the efficacy of induction chemotherapy followed by radiotherapy, with regards to the response and survival rate for stage IV hypopharyngeal cancer patients, was examined.

Materials and Methods: From July 1998 to February 2000, 18 cases were diagnosedas AJCC stage IV hypopharyngeal cancer without distant metastasis. These patients were treated with induction chemotherapy followed by radiotherapy, and the results retrospectively analyzed. The regimen of the induction chemotherapy was the 5-FU and cisplatincombination, at 3-week intervals for, 2 cycles. The total radiation dose for the primary lesion and metastatic lymph nodes was 68.4¢¦72.0 Gy (median: 70.2 Gy).

Results: The median follow up period was 28 months, ranging from 7 to 99 months. The 3-year overall survival and disease-free survival rate were 41.7 and 31.1%, respectively. In 6 cases (33.3%), conservation of the larynx for over 3 years was possible. After the induction chemotherapy there were 16 partial responses (88.8%), 1 complete response and 1 with no response (5.6% each), therefore, 17 of the 18 cases (94.6%) showed responses. After the completion of the induction chemotherapy and radiotherapy, a complete response was noted in 13 cases (72.2%), a partial response in 5 (27.8%), with an overall response rate of 100%. In the analysis of the prognostic factors influencing the survival rate, the 3-year and disease-free survival rates for the complete and partial response groups were 43.1, and 20.0%, and 39.6, and 20.0%, respectively (p=0.0003, p=0.002). Only the final response after treatment completion was statistically significant.

Conclusion: For stage IV hypopharyngeal cancer, induction chemotherapy followed by radiotherapy was an effective treatment, with no severe side effects.

Å°¿öµå

ÇÏÀεξÏ;Ç×¾ÏÈ­Çпä¹ý;¹æ»ç¼±Ä¡·á;Hypopharyngeal cancer;Chemotherapy;Radiotherapy

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS